clinical trials

Madrigal Mental Care Develops Psychedelic Drug Treatment for Post-Traumatic Stress Disorder

Novel Nasal-Spray Nano-Formulation Enables Nose-To-Brain Delivery of Biodegradable Nanoparticles that can Encapsulate Psychedelic Substances such as Psilocybin Madrigal Mental Care, a biopharmaceutical company developing a breakthrough delivery system for psychedelic drugs, introduced its novel nanotechnology for the treatment and prevention of post-traumatic stress disorder (PTSD) at Biomed Israel 2022, the premier international Life Science and …

Madrigal Mental Care Develops Psychedelic Drug Treatment for Post-Traumatic Stress Disorder Read More »

New UCSF Research Program to Advance Psychedelics Research and Treatments

Psychedelics research in support of brain health is getting a major boost this month with the formation of the Neuroscape Psychedelics Division at the University of California, San Francisco (UCSF). Through $6.4M in private funding, the new division will take a unique translational research approach to integrate cutting-edge neuroscience technology with psychedelics treatment, including through …

New UCSF Research Program to Advance Psychedelics Research and Treatments Read More »

Hundreds of Canadians Already Struggling With Mental Health Conditions Plead for Access to Psychedelic Medicine

ATMA and SYNTAC Institute Collaborate to Submit a Group Application for Section 56 Exemption from Health Canada to Access Psychedelic Therapy ATMA Journey Centers Inc. (ATMA), an Alberta-based company focused on delivering innovative psychedelic-assisted therapies internationally, announced today that it has submitted a Group Application for Section 56 Exemption to Health Canada on behalf of Canadians …

Hundreds of Canadians Already Struggling With Mental Health Conditions Plead for Access to Psychedelic Medicine Read More »

Scroll to Top